The relationship between KRAS mutation and PDL1 expression was independent of tumor site, though the effect in metastatic tumors did not reach statistical significance because of the small size of this group and low frequency of KRAS mutations (Fig. 2J). This evidence concerns the gene CD274 and neoplasm.